Revolution of CRISPR Technologies: Applications, Limitations, and Implications for the Future of Gene Therapy in Indonesia
DOI:
10.29303/jbt.v26i1.11547Published:
2026-04-15Downloads
Abstract
Gene editing has emerged as a transformative approach in biomedical science, enabling precise modification of genomic sequences to investigate gene function and develop novel therapeutic strategies. Among available technologies, CRISPR-Cas9 has revolutionized genome engineering due to its simplicity, programmability, high efficiency, and cost-effectiveness. This review examines the mechanisms, biomedical applications, limitations, ethical considerations, and future prospects of CRISPR technology, with particular emphasis on its relevance to gene therapy in Indonesia. CRISPR has demonstrated significant potential in treating monogenic disorders such as β-thalassemia and sickle cell disease, advancing cancer research through gene targeting and immunotherapy, and enabling innovative antiviral strategies and molecular diagnostics. These applications highlight its potential to provide precise and potentially curative therapies. However, several challenges remain, including off-target effects, limitations in delivery systems, biological complexity, and uncertainties regarding long-term safety. Ethical concerns, particularly related to germline editing, informed consent, and social equity, further complicate its clinical application. In Indonesia, CRISPR development is still at an early stage, with applications largely limited to research settings. Key challenges include limited infrastructure, insufficient expertise, evolving regulatory frameworks, and low public awareness. In conclusion, CRISPR holds strong potential for advancing gene therapy in Indonesia, but its successful implementation requires strengthened regulation, improved infrastructure, capacity building, and greater public engagement to ensure safe and ethical use.
Keywords:
Biomedical application CRISPR-Cas9 Gene therapy Genome editingReferences
Baddeley, H. J. E., & Isalan, M. (2021). The application of CRISPR/CAS systems for antiviral therapy. Frontiers in Genome Editing, 3, 745559. https://doi.org/10.3389/fgeed.2021.745559
Biswas, I. (2025). Ethical dimensions and societal implications: ensuring the social responsibility of CRISPR technology. Frontiers in Genome Editing, 7, 1593172. https://doi.org/10.3389/fgeed.2025.1593172
Buddle, E. A., Lawi, G. F. K., & Leach, J. (2025). “They ignore social issues”: understanding the diversity of perspectives on plant gene technologies in Indonesia. Plant Cell Reports, 44(8), 178. https://doi.org/10.1007/s00299-025-03564-0
Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236. https://doi.org/10.1038/s41586-020-1978-5
Estevam, I., Neto, C., Marques, F., Gentile, C., Lima, E., Mota, E., Costa, G., Feitosa, G., Filho, V., & Noronha, M. (2024). Discoveries of gene editing using crispr-cas9 for the treatment of sickle cell disease: a literature review. Hematology Transfusion and Cell Therapy, 46, S1138. https://doi.org/10.1016/j.htct.2024.09.1990
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y., Domm, J., Eustace, B. K., Foell, J., De La Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., De Montalembert, M., Rondelli, D., . . . Corbacioglu, S. (2020). CRISPR-CAS9 gene editing for sickle cell disease and Β-Thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/nejmoa2031054
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., . . . Lebwohl, D. (2021). CRISPR-CAS9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493–502. https://doi.org/10.1056/nejmoa2107454
Huang, T., Zhang, R., & Li, J. (2022). CRISPR-Cas-based techniques for pathogen detection: Retrospect, recent advances, and future perspectives. Journal of Advanced Research, 50, 69–82. https://doi.org/10.1016/j.jare.2022.10.011
Jameel, Z. I. (2026). CRISPR-Cas9 technology: a breakthrough in cancer gene therapy. Egyptian Journal of Medical Human Genetics, 27(1). https://doi.org/10.1186/s43042-025-00833-1
Kharbikar, L., Konwarh, R., Chakraborty, M., Nandanwar, S., Marathe, A., Yele, Y., Ghosh, P. K., Sanan-Mishra, N., & Singh, A. P. (2023). 3Bs of CRISPR-Cas mediated genome editing in plants: exploring the basics, bioinformatics and biosafety landscape. Physiology and Molecular Biology of Plants, 29(12), 1825–1850. https://doi.org/10.1007/s12298-023-01397-3
Knott, G. J., & Doudna, J. A. (2018). CRISPR-Cas guides the future of genetic engineering. Science, 361(6405), 866–869. https://doi.org/10.1126/science.aat5011
Kosicki, M., Tomberg, K., & Bradley, A. (2018). Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nature Biotechnology, 36(8), 765–771. https://doi.org/10.1038/nbt.4192
Kulkarni, C. R., Prajnashree, A., & Nyamagoud, S. B. (2025). CRISPR technology in antiviral therapy: advancements, applications, and implications. D Y Patil Journal of Health Sciences, 13(1), 25–31. https://doi.org/10.4103/dypj.dypj_2_25
Ma, Y., & Liao, Y. (2026). CRISPR-mediated cancer therapies: Approaches to direct tumor targeting. Critical Reviews in Oncology/Hematology, 222, 105277. https://doi.org/10.1016/j.critrevonc.2026.105277
Mayorga-Ramos, A., Zúñiga-Miranda, J., Carrera-Pacheco, S. E., Barba-Ostria, C., & Guamán, L. P. (2023). CRISPR-CAS-Based Antimicrobials: design, challenges, and bacterial mechanisms of Resistance. ACS Infectious Diseases, 9(7), 1283–1302. https://doi.org/10.1021/acsinfecdis.2c00649
Motta, B. M., Pramstaller, P. P., Hicks, A. A., & Rossini, A. (2017). The impact of CRISPR/CAS9 technology on cardiac research: From disease modelling to therapeutic approaches. Stem Cells International, 2017, 1–13. https://doi.org/10.1155/2017/8960236
Murillo, L. L., Green, M., Mahon, N., Saiani, A., & Tsigkou, O. (2025). Modelling Cancer pathophysiology: Mechanisms and changes in the extracellular matrix during cancer initiation and early tumour growth. Cancers, 17(10), 1675. https://doi.org/10.3390/cancers17101675
Nguyen, A. H., & Quang, M. T. (2025). CRISPR/CAS9 Genome editing in Oncology: mechanisms, therapeutic platforms and translational challenges. Molecular Biotechnology. https://doi.org/10.1007/s12033-025-01533-2
Nouri, F., Alibabaei, F., Forouzanmehr, B., Tahmasebi, H., Oksenych, V., & Eslami, M. (2025). Progress in CRISPR technology for antiviral treatments: Genome editing as a potential cure for chronic viral infections. Microbiology Research, 16(5), 104. https://doi.org/10.3390/microbiolres16050104
Pickar-Oliver, A., & Gersbach, C. A. (2019). The next generation of CRISPR–Cas technologies and applications. Nature Reviews Molecular Cell Biology, 20(8), 490–507. https://doi.org/10.1038/s41580-019-0131-5
Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M., Alsubki, R. A., Alahmed, H. E., Al-Abdulhadi, S., Alhashem, F. A., Alqatari, A. A., Alsayyah, A., Farahat, R. A., Abdulal, R. H., Al-Ahmed, A. H., . . . Mohapatra, R. K. (2023). Application of CRISPR/CAS9 technology in cancer treatment: a future direction. Current Oncology, 30(2), 1954–1976. https://doi.org/10.3390/curroncol30020152
Raffaele, I., Cipriano, G. L., Anchesi, I., Oddo, S., & Silvestro, S. (2025). CRISPR/CAS9 and IPSC-Based Therapeutic Approaches in Alzheimer’s Disease. Antioxidants, 14(7), 781. https://doi.org/10.3390/antiox14070781
Sen, D., & Mukhopadhyay, P. (2024). Antimicrobial resistance (AMR) management using CRISPR-Cas based genome editing. Gene and Genome Editing, 7, 100031. https://doi.org/10.1016/j.ggedit.2024.100031
Sumiati, Fadilah, R., Darmawan, A., & Nadia, R. (2025). — Invited Review — Challenges and constraints to the sustainability of poultry farming in Indonesia. Animal Bioscience, 38(4), 802–817. https://doi.org/10.5713/ab.24.0678
Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2021). Β-Thalassemias. New England Journal of Medicine, 384(8), 727–743. https://doi.org/10.1056/nejmra2021838
Taher, M., Aminondin, S. ‘., Nasir, N. A., Jasmadi, N. A., Nizam, N. I. N., Shahrul, I. S., Susanti, D., Khotib, J., Faiyazuddin, M., Widodo, R. T., & Haris, M. S. (2025). Sickle cell disease: understanding pathophysiology, clinical features and advances in gene therapy approaches. Frontiers in Pharmacology, 16, 1630994. https://doi.org/10.3389/fphar.2025.1630994
Wiley, L., Cheek, M., LaFar, E., Ma, X., Sekowski, J., Tanguturi, N., & Iltis, A. (2024). The ethics of human embryo editing via CRISPR-CAS9 technology: a systematic review of ethical arguments, reasons, and concerns. HEC Forum, 37(2), 267–303. https://doi.org/10.1007/s10730-024-09538-1
License
Copyright (c) 2026 Endeh Apriyanti, Ahsanal Kasasiah, Aliya Azkia Zahra, Aliza Salsabila Ainaputri, Cantika Aprillia, Dewi Pratiwi Purba Siboro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
